267 related articles for article (PubMed ID: 9530363)
21. Effect of the preestrogen 4-androstene-3,17-dion-19-al on the Dunning R3327 prostatic adenocarcinoma.
Marks TA; Petrow V
Cancer Res; 1983 Aug; 43(8):3687-90. PubMed ID: 6861138
[TBL] [Abstract][Full Text] [Related]
22. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
23. Leuprorelin acetate in prostate cancer: a European update.
Persad R
Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
[TBL] [Abstract][Full Text] [Related]
24. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
[TBL] [Abstract][Full Text] [Related]
25. Early effects of pharmacological androgen deprivation in human prostate cancer.
Mercader M; Sengupta S; Bodner BK; Manecke RG; Cosar EF; Moser MT; Ballman KV; Wojcik EM; Kwon ED
BJU Int; 2007 Jan; 99(1):60-7. PubMed ID: 17227493
[TBL] [Abstract][Full Text] [Related]
26. Effect of the 5 alpha-reductase inhibitor PNU 156765, alone or in combination with flutamide, in the Dunning R3327 prostatic carcinoma model in rats.
Zaccheo T; Giudici D; Panzeri A; di Salle E
Chemotherapy; 1998; 44(4):284-92. PubMed ID: 9681205
[TBL] [Abstract][Full Text] [Related]
27. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
Akaza H
BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
[TBL] [Abstract][Full Text] [Related]
28. A high-fat diet does not influence the growth of the Dunning R3327-H transplantable prostate adenocarcinoma.
Schwab ED; Normolle D; Pacis RA; Cho SS; Pienta KJ
Anticancer Res; 1998; 18(5A):3603-7. PubMed ID: 9858946
[TBL] [Abstract][Full Text] [Related]
29. Effect of early and delayed difluoromethylornithine pretreatment upon cyclophosphamide chemotherapy.
Johnson M; Shaw M; Rubenstein M; Guinan P
Clin Physiol Biochem; 1990; 8(1):11-5. PubMed ID: 2108838
[TBL] [Abstract][Full Text] [Related]
30. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
31. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
32. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
33. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma.
Ip MM; Milholland RJ; Rosen F
Cancer Res; 1980 Jul; 40(7):2188-93. PubMed ID: 7388787
[TBL] [Abstract][Full Text] [Related]
34. Preliminary investigation of the nasal delivery of liposomal leuprorelin acetate for contraception in rats.
Shahiwala A; Misra A
J Pharm Pharmacol; 2006 Jan; 58(1):19-26. PubMed ID: 16393460
[TBL] [Abstract][Full Text] [Related]
35. [A case of prostate cancer treated with combined androgen-blockade].
Kurita M; Kato Y; Tamura Y; Suzuki K; Yamanaka H
Gan To Kagaku Ryoho; 2000 Feb; 27(2):307-10. PubMed ID: 10700907
[TBL] [Abstract][Full Text] [Related]
36. Newer methods of hormonal therapy for prostate cancer.
Soloway MS
Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
[TBL] [Abstract][Full Text] [Related]
37. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
39. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
40. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
Isaacs JT
Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]